IceCure Medical Announces Release Of A Study Published In 'Cancers,' Demonstrating Safety And Efficacy Of ProSense; Disease-free Survival Rate Was 92% At Median Follow-Up Of 26 And A Half Months
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical announced the publication of a study in 'Cancers' showing the safety and efficacy of its ProSense system. The study reported a 92% disease-free survival rate at a median follow-up of 26.5 months.
November 28, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of a positive study on IceCure Medical's ProSense system could boost investor confidence, potentially leading to a short-term uptick in ICCM's stock price.
The release of a study demonstrating the safety and efficacy of a company's product typically has a positive impact on the company's stock price, as it may lead to increased adoption and sales. With a high disease-free survival rate reported, investor sentiment is likely to be bolstered, potentially increasing demand for ICCM shares in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100